Suscripción a Biblioteca: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Publicado 4 números por año

ISSN Imprimir: 0731-8898

ISSN En Línea: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 1)

Volumen 22, Edición 3, 2003, 34 pages
DOI: 10.1615/JEnvPathToxOncol.v22.i3.40
Get accessGet access

SINOPSIS

Throughout most of the past century, physicians could offer patients no treatments for infections caused by viruses. The experience with treatment of infection by human immunodeficiency virus (HIV) has changed the way healthcare workers deal with viral infections and has triggered a growing rate of discovery and use of antiviral agents, the first fruits of the expanding genomics revolution. HIV treatment also provides an informative paradigm for pharmacogenomics because control of infection and its consequences is limited by the development of viral drug resistance and by host factors. This report summarizes studies published to date on the significance of testing of HIV-1 resistance to antiretroviral drugs. The only Food and Drug Administration-approved kit for HIV drug resistance testing by genotypic sequencing is commercially available through Visible Genetics, Inc. Genotyping sequencing alone is most likely an adequate test to assist in the therapeutic decision-making process for previous regimen failure, for treatment-naive patients in areas of high prevalence of transmitted resistant virus, and for pregnant women. However, in exceptional cases of highly complex mutation patterns and extensive cross-resistance, it may be useful to obtain a phenotype test, because that result may more easily identify drugs to which virus is least resistant. There are no published clinical trials results on the usefulness of the so-called virtual phenotype over genotypic sequencing alone. Not only has the paradigm of viral pharmacogenomics in the form of HIV genotypic sequencing been useful in treating other viral diseases, but it is also important to the real-life implementation of the growing discipline of genomics or molecular medicine. The application of this paradigm to the thousands of potential therapeutic targets that have become available through the various human genome projects will certainly gradually change the landscape of diagnosis and management of many diseases, including cancer.

CITADO POR
  1. Stebbing Justin, Bower Mark, Comparative pharmacogenomics of antiretroviral and cytotoxic treatments, The Lancet Oncology, 7, 1, 2006. Crossref

  2. Klimas Nancy, Koneru Anne O’Brien, Fletcher Mary Ann, Overview of HIV, Psychosomatic Medicine, 70, 5, 2008. Crossref

  3. Guo Yingying, Shafer Steven, Weller Paul, Usuka Jonathan, Peltz Gary, Pharmacogenomics and drug development, Pharmacogenomics, 6, 8, 2005. Crossref

712 Vistas de artículos 8 Descargas de artículos Métrica
712 PUNTOS DE VISTA 8 DESCARGAS 3 Crossref CITAS Google
Scholar
CITAS

Artículos con contenido similar:

Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 2) Journal of Environmental Pathology, Toxicology and Oncology, Vol.22, 2003, issue 4
Nancy G. Klimas, Margaret Marchette, Charles Mitchell, Eduardo Meneses Sierra, Alejandro Isava, Dushyantha Jayaweera, Enriqueta Nunez, J. Brian Page, Gwendolyn Scott, Roberto Patarca, Nelson J. Rodriguez, Mary Ann Fletcher, Delia Rivera, Michael Kolber, Mirtha M. Sanabia, Rafael Campo, Cindy W. Mask, Jose Moreno, Michael Alter, Ricardo Vallejo, Catherine Boulanger
Human Papilloma Virus−Associated Oral Pharyngeal Squamous Cell Carcinoma: Prevalence, Prevention, and Awareness of Vaccination in the Indian Population Critical Reviews™ in Oncogenesis, Vol.28, 2023, issue 2
Ragini D. Singh, Naveen Chaudhary, Smitha Mathews, Vigi Chaudhary
Drug Development for Metastasis Prevention Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Steven M. Dubinett, Yari Fontebasso
Diagnostic Modalities for the Detection of SARS-CoV-2: Principles, Advantages, and Pitfalls Critical Reviews™ in Biomedical Engineering, Vol.48, 2020, issue 4
Suresh Anand BS, Ilamaran M, Jonath Sujan, Ashwin Kumar N
COVID-19 Threat to the World: Current and Possible Diagnostic/Treatment Strategies Critical Reviews™ in Biomedical Engineering, Vol.49, 2021, issue 1
Saima Wajid, Mohd Mughees, Himanshu Chugh, Samar Husain Naqvi
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain